One of the most valuable things you can do to help the pituitary community is share your own experience. What you have lived through helps others understand the realities of living with acromegaly, or any other disease. It helps clinicians see challenges that never show up in a lab result and helps make sure that programs and services are built on patients needs. Taking part in research and using your voice is one of the most direct ways to do that.
MAR002 is an early, promising development: a new take on a proven strategy, with the potential for stronger IGF-1 control and dramatically less frequent dosing. At the same time, it’s important to keep expectations grounded. The drug is still investigational. It is not approved, not yet available outside clinical trials, and a larger patient study is needed to confirm what the early data suggest.
How should clinicians define disease control, select therapy, and personalize treatment for people living with acromegaly? A new three-part podcast series from The Pituitary Society explores these questions through the lens of the updated international consensus recommendations on therapeutic outcomes in acromegaly (Melmed S et al. Nat Rev Endocrinol 2025;21:718–37).
In this episode, Dr. Mario Maldonado from Recordati Rare Diseases discusses recent advances in endocrinology, focusing on hypercortisolism, diagnostic challenges, and innovative treatments. He shares insights from clinical studies and the future of AI in disease management.
From Linda M. Rio, PWN contributor and mental health professional – In recent years, it has been more and more recognized that medical illnesses, procedures, interventions, and personal encounters can sometimes be experienced as traumatic,
From J D Faccinetti, cofounder and chief editor - My guest today on the Pituitary Podcast is someone I've had the pleasure of knowing since 2019, Risa August. Risa is a patient advocate, an author,
We are very pleased to announce our latest book on Prolactinomas. This is the 6th book in a series that includes tomes on Cushing’s, Hypopituitarism, Vasopressin Deficiency (formerly Diabetes Insipidus), Pituitary Adenomas, and Pituitary Disorders. The Prolactinomas book is available here and in all major book retailers.
In the final episode, Professor Maria Fleseriu and Professor Mônica Gadelha discuss the updated treatment algorithm, treatment sequencing, and management approaches for patients with resistant disease. Listen to the audio version of the podcast here
Professor Maria Fleseriu and Professor Mark Gurnell focus on predictors of response to medical therapy, including the role of imaging characteristics, pathological and molecular markers, and biochemical parameters in guiding treatment decisions to support individualized
After years of clinical suspicion, large studies confirm elevated risk across multiple cancers From Lewis S Blevins Jr., MD – Professor of Neurological Surgery, Medical Director of the California Center for Pituitary Disorders at UCSF
In the opening episode, Professor Maria Fleseriu and Professor Shlomo Melmed discuss the development of the consensus recommendations and explore how remission and disease control should be defined and assessed in clinical practice. They also
In this engaging discussion, we touch on why muscles stay weak in acromegaly even after the disease is under control, and why hypercortisolism keeps turning up in more people than anyone used to expect. Dr. Valassi’s earlier work on acromegaly and muscles got a lot of attention from PWN readers.